AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule ...

Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...

Zymeworks Inc. (NYSE:ZYME – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven research firms ...

Explore Repligen's Q4 2024 earnings insights, highlighting strong non-COVID growth, standout CDMO performance, innovative product launches, and ...

Key achievements included positive Phase 3 ASPEN data for brensocatib in bronchiectasis, record-breaking ARIKAYCE revenues, and advancements in other pipeline programs such as TPIP and ARIKAYCE's ...

Hourglass Capital LLC grew its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 12.6% during the fourth quarter, ...

Q4 2024 Management View Co-CEO Helmy Eltoukhy highlighted record revenue of $202 million in Q4 2024, driven by 30% year-over-year growth, with total 2024 revenue reaching $739 million, a 31% increase.

The company will request a priority review, which Leerink Partners analysts believe is likely to be granted as there are no approved therapies for FSGS. Given that the understanding around ...

Both live webcasts can also be accessed under “Events & Presentations” on the Investors section of the Tectonic website at www.tectonictx.com. Once these conferences have concluded, a replay of the ...

Good day, ladies and gentlemen, and welcome to Repligen Corporation's fourth quarter of 2024 earnings conference call. My name is MJ, and I will be your coordinator. (Operator Instructions) I would ...